TY - JOUR
T1 - Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials
AU - Schuetz, Philipp
AU - Bolliger, Rebekka
AU - Merker, Meret
AU - Christ-Crain, Mirjam
AU - Stolz, Daiana
AU - Tamm, Michael
AU - Luyt, Charles E.
AU - Wolff, Michel
AU - Schroeder, Stefan
AU - Nobre, Vandack
AU - Reinhart, Konrad
AU - Branche, Angela
AU - Damas, Pierre
AU - Nijsten, Maarten
AU - Deliberato, Rodrigo O.
AU - Verduri, Alessia
AU - Beghé, Bianca
AU - Cao, Bin
AU - Shehabi, Yahya
AU - Jensen, Jens Ulrik S.
AU - Beishuizen, Albertus
AU - de Jong, Evelien
AU - Briel, Matthias
AU - Welte, Tobias
AU - Mueller, Beat
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.
AB - Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.
KW - antibiotic stewardship
KW - pneumonia
KW - Procalcitonin
KW - respiratory infection
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85051549065&partnerID=8YFLogxK
U2 - 10.1080/14787210.2018.1496331
DO - 10.1080/14787210.2018.1496331
M3 - Review Article
C2 - 29969320
AN - SCOPUS:85051549065
SN - 1478-7210
VL - 16
SP - 555
EP - 564
JO - Expert Review of Anti-Infective Therapy
JF - Expert Review of Anti-Infective Therapy
IS - 7
ER -